Could This Medicine Be the Next Winner for Novartis?

The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.

Related Keywords

Switzerland ,Regeneron Dupixent ,Novartis ,Drug Administration ,Analytics Market Research ,Market Research ,